Compare DFTX & CPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DFTX | CPB |
|---|---|---|
| Founded | N/A | 1869 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Packaged Foods |
| Sector | | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 6.6B |
| IPO Year | 2020 | 1994 |
| Metric | DFTX | CPB |
|---|---|---|
| Price | $44.91 | $23.95 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 18 |
| Target Price | ★ $38.50 | $26.06 |
| AVG Volume (30 Days) | 2.1M | ★ 5.6M |
| Earning Date | 05-04-2026 | 06-01-2026 |
| Dividend Yield | N/A | ★ 7.63% |
| EPS Growth | N/A | ★ 6.35 |
| EPS | N/A | ★ 1.55 |
| Revenue | N/A | ★ $10,253,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $0.11 |
| P/E Ratio | ★ N/A | $15.34 |
| Revenue Growth | N/A | ★ 6.40 |
| 52 Week Low | $14.62 | $19.56 |
| 52 Week High | $49.70 | $34.18 |
| Indicator | DFTX | CPB |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 61.57 |
| Support Level | $40.46 | $20.98 |
| Resistance Level | $45.42 | $31.93 |
| Average True Range (ATR) | 2.76 | 0.67 |
| MACD | -0.07 | 0.11 |
| Stochastic Oscillator | 49.56 | 81.63 |
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.